IGC Pharma (IGC) Assets (2011 - 2026)

IGC Pharma (IGC) has reported Assets for 16 consecutive years, with $9.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Assets rose 5.01% year-over-year to $9.2 million in Q1 2026; TTM through Mar 2026 was $9.2 million, a 5.01% increase from a year earlier, with the FY2026 full-year figure at $9.2 million, up 5.01% from the prior year.
• Assets was $9.2 million for Q1 2026 at IGC Pharma, down from $9.7 million in the prior quarter.
• Over five years, Assets peaked at $26.8 million in Q1 2022 and troughed at $7.9 million in Q2 2025.
• A 5-year average of $14.1 million and a median of $10.6 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets sank 43.9% in 2023 and rose 6.98% in 2025, its largest moves.
• Over 5 years, Assets stood at $20.1 million in 2022, then slumped by 43.9% to $11.3 million in 2023, then dropped by 19.37% to $9.1 million in 2024, then gained by 6.98% to $9.7 million in 2025, then fell by 5.43% to $9.2 million in 2026.
• The last three Assets figures came in at $9.2 million (Q1 2026), $9.7 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.